Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AVADEL PHARMACEUTICALS PLC (AVDL)
|
Add to portfolio |
|
|
|
| Price: |
$8.54
| | Metrics |
| OS: |
89.4
|
M
| |
|
|
| Market cap: |
$763
|
M
| |
|
|
|
Net cash:
|
$140
|
M
| |
$1.56
|
per share
|
|
EV:
|
$624
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($94.0)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 22.3 | 59.2 | 103.3 | 173.2 | 150.2 | 173.0 | 15.0 |
| Revenue growth | -100.0% | -62.3% | -42.7% | -40.4% | 15.3% | -13.2% | 1055.3% | 258.3% |
| Cost of goods sold | -0.1 | 5.7 | 12.1 | 17.5 | 16.3 | 13.2 | 11.4 | 3.4 |
| Gross profit | 0.1 | 16.6 | 47.1 | 85.8 | 156.9 | 137.0 | 161.6 | 11.6 |
| Gross margin | | 74.3% | 79.5% | 83.0% | 90.6% | 91.2% | 93.4% | 77.4% |
| Selling, general and administrative | 68.5 | 32.4 | 30.2 | 100.4 | 58.9 | 44.2 | 21.7 | 15.7 |
| Research and development | 17.1 | 20.4 | 32.9 | 39.3 | 33.4 | 34.6 | 25.6 | 17.3 |
| EBITA | -85.5 | -36.2 | -25.1 | -55.0 | 64.7 | 58.2 | 114.3 | -24.4 |
| EBITA margin | | -162.1% | -42.4% | -53.2% | 37.3% | 38.7% | 66.1% | -163.1% |
| Amortization of intangibles | | 0.4 | 0.8 | 6.6 | 3.7 | 13.9 | 12.6 | 11.7 |
| EBIT | -85.5 | -36.6 | -25.9 | -61.6 | 61.0 | 44.3 | 101.7 | -36.2 |
| EBIT margin | | -164.0% | -43.8% | -59.6% | 35.2% | 29.5% | 58.8% | -241.5% |
| Pre-tax income | -93.1 | -5.1 | -38.6 | -113.2 | 92.7 | -9.7 | 77.7 | -90.1 |
| Income taxes | -15.8 | -12.1 | -5.4 | -17.9 | 24.4 | 31.6 | 35.9 | -0.6 |
| Tax rate | 17.0% | 238.3% | 13.9% | 15.8% | 26.3% | | 46.2% | 0.7% |
| Earnings from continuing ops | -77.3 | 7.0 | -33.2 | -95.3 | 68.3 | -41.3 | 41.8 | -93.5 |
| Earnings from discontinued ops | | | | | | | | 4.0 |
| Net income | -77.3 | 7.0 | -33.2 | -95.3 | 68.3 | -41.3 | 41.8 | -89.5 |
| Net margin | | 31.5% | -56.1% | -92.3% | 39.4% | -27.5% | 24.2% | -597.6% |
| |
| Diluted EPS | ($1.32) | $0.13 | ($0.89) | ($2.55) | $1.63 | ($1.00) | $0.96 | ($2.58) |
| Shares outstanding (diluted) | 58.5 | 54.9 | 37.4 | 37.3 | 41.8 | 41.2 | 43.6 | 36.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|